{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T04:29:58Z","timestamp":1786422598809,"version":"build-2736575974"},"reference-count":71,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"9","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,9]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Children experience lower rates of symptomatic and severe coronavirus disease 2019 (COVID-19) than adults, potentially due to cross-reactive immunity from prior endemic human coronavirus (HCoV) infections. However, epidemiologic longitudinal evidence supporting this mechanism in children remains limited. In 2021, outbreaks of HCoV-NL63 and HCoV-OC43 occurred in Furano, Japan.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>This prospective longitudinal cohort study was conducted at a single hospital in Furano. The primary outcome was time to onset of symptomatic COVID-19. Children with HCoV-NL63 (weeks 1\u201321) or HCoV-OC43 (weeks 22\u201333) infections were compared with children infected with other respiratory viruses. Analyses included Kaplan\u2013Meier estimation, log-rank tests, and multivariate Cox regression.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      A total of 237 children were followed for up to 700 days. Cumulative incidence analyses demonstrated a significantly reduced risk of symptomatic COVID-19 in the HCoV-NL63 group through day 700 (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.03), whereas no protective effect was observed for HCoV-OC43. In multivariable analyses, prior HCoV-NL63 infection was associated with significant protection at 500 days (95% confidence interval [CI]: 0.05\u20130.54), 600 days (95% CI: 0.07\u20130.45), and 700 days (95% CI: 0.19\u20130.80), but not at earlier time points. HCoV-OC43 showed no significant association at any time point.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>Prior HCoV-NL63 infection, but not HCoV-OC43, was associated with reduced risk of symptomatic COVID-19 in children for up to 700 days. These findings provide epidemiologic support for virus-specific cross-reactive immunity and highlight pediatric\u2013adult differences. These findings are not yet generalizable and require validation in studies using serological markers and stricter confounder control.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/inf.0000000000005200","type":"journal-article","created":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T05:01:07Z","timestamp":1772168467000},"page":"776-782","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Protective Association of Endemic HCoV-NL63 With Symptomatic COVID-19 in a Pediatric Cohort"],"prefix":"10.1097","volume":"45","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9196-2656","authenticated-orcid":false,"given":"Fujio","family":"Kakuya","sequence":"first","affiliation":[{"name":"Department of Pediatrics, Furano Kyokai Hospital, Furano, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yutaka","family":"Saisho","sequence":"additional","affiliation":[{"name":"Department of Medical Innovation, Medical Center for Translational Research, University of Osaka Hospital, Osaka, Japan"},{"name":"Center for Advanced Modality and Drug Delivery System, University of Osaka, Osaka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryuta","family":"Terao","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Furano Kyokai Hospital, Furano, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hitoshi","family":"Okubo","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Furano Kyokai Hospital, Furano, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroaki","family":"Fujiyasu","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Furano Kyokai Hospital, Furano, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fumie","family":"Inyaku","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Furano Kyokai Hospital, Furano, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahiro","family":"Kinebuchi","sequence":"additional","affiliation":[{"name":"Department of Clinical Laboratory, Furano Kyokai Hospital, Furano, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,2,27]]},"reference":[{"key":"R1-20260811","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1001\/jama.2020.2648","article-title":"Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention.","volume":"323","author":"Wu","year":"2020","journal-title":"JAMA"},{"key":"R2-20260811","doi-asserted-by":"crossref","first-page":"422","DOI":"10.15585\/mmwr.mm6914e4","article-title":"Coronavirus disease 2019 in children\u2014United States, February 12\u2013April 2, 2020.","volume":"69","year":"2020","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"R3-20260811","doi-asserted-by":"crossref","first-page":"13903","DOI":"10.1038\/s41598-021-92500-9","article-title":"Children\u2019s role in the COVID-19 pandemic: a systematic review of early surveillance data on susceptibility, severity, and transmissibility.","volume":"11","author":"Gaythorpe","year":"2021","journal-title":"Sci Rep"},{"key":"R4-20260811","first-page":"100405","article-title":"Severe COVID-19 outcomes in pediatrics: an observational cohort analysis comparing Alpha, Delta, and Omicron variants.","volume":"18","author":"Bahl","year":"2023","journal-title":"Lancet Reg Health Am"},{"key":"R5-20260811","doi-asserted-by":"crossref","first-page":"129","DOI":"10.37737\/ace.22016","article-title":"Age-specific mortality associated with COVID-19 and seasonal influenza in Japan: using multiple population-based databases.","volume":"4","author":"Noda","year":"2022","journal-title":"Ann Clin Epidemiol"},{"key":"R6-20260811","doi-asserted-by":"crossref","first-page":"e148694","DOI":"10.1172\/jci.insight.148694","article-title":"Natural mucosal barriers and COVID-19 in children.","volume":"6","author":"Pierce","year":"2021","journal-title":"JCI Insight"},{"key":"R7-20260811","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1038\/s41587-021-01037-9","article-title":"Pre-activated antiviral innate immunity in the upper airways controls early SARS-CoV-2 infection in children.","volume":"40","author":"Loske","year":"2022","journal-title":"Nat Biotechnol"},{"key":"R8-20260811","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1038\/s41586-021-04345-x","article-title":"Local and systemic responses to SARS-CoV-2 infection in children and adults.","volume":"602","author":"Yoshida","year":"2022","journal-title":"Nature"},{"key":"R9-20260811","doi-asserted-by":"crossref","first-page":"109773","DOI":"10.1016\/j.celrep.2021.109773","article-title":"Robust innate responses to SARS-CoV-2 in children resolve faster than in adults without compromising adaptive immunity.","volume":"37","author":"Vono","year":"2021","journal-title":"Cell Rep"},{"key":"R10-20260811","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1038\/s41590-021-01089-8","article-title":"Children develop robust and sustained cross-reactive spike-specific immune responses to SARS-CoV-2 infection.","volume":"23","author":"Dowell","year":"2022","journal-title":"Nat Immunol"},{"key":"R11-20260811","doi-asserted-by":"crossref","first-page":"100557","DOI":"10.1016\/j.xcrm.2022.100557","article-title":"Rapid synchronous type 1 IFN and virus-specific T cell responses characterize first wave non-severe SARS-CoV-2 infections.","volume":"3","author":"Chandran","year":"2022","journal-title":"Cell Rep Med"},{"key":"R12-20260811","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1126\/science.abd3871","article-title":"Selective and cross-reactive SARS-CoV-2 T cell epitopes in unexposed humans.","volume":"370","author":"Mateus","year":"2020","journal-title":"Science"},{"key":"R13-20260811","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1038\/s41586-020-2598-9","article-title":"SARS-CoV-2-reactive T cells in healthy donors and patients with COVID-19.","volume":"587","author":"Braun","year":"2020","journal-title":"Nature"},{"key":"R14-20260811","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1016\/j.cell.2020.05.015","article-title":"Targets of T cell responses to SARS-CoV-2 coronavirus in humans with COVID-19 disease and unexposed individuals.","volume":"181","author":"Grifoni","year":"2020","journal-title":"Cell"},{"key":"R15-20260811","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1038\/s41586-020-2550-z","article-title":"SARS-CoV-2-specific T cell immunity in cases of COVID-19 and SARS, and uninfected controls.","volume":"584","author":"Le Bert","year":"2020","journal-title":"Nature"},{"key":"R16-20260811","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1093\/infdis\/jiaa161","article-title":"Coronavirus occurrence and transmission over 8 years in the HIVE cohort of households in Michigan.","volume":"222","author":"Monto","year":"2020","journal-title":"J Infect Dis"},{"key":"R17-20260811","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/j.jiac.2023.11.012","article-title":"Epidemiology of endemic human coronavirus infection during the COVID-19 pandemic.","volume":"30","author":"Kakuya","year":"2024","journal-title":"J Infect Chemother"},{"key":"R18-20260811","doi-asserted-by":"crossref","first-page":"13396","DOI":"10.1073\/pnas.1516698112","article-title":"Cross-immunity between strains explains the dynamical pattern of paramyxoviruses.","volume":"11","author":"Bhattacharyya","year":"2015","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R19-20260811","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1126\/science.1185181","article-title":"Cross-reacting antibodies enhance dengue virus infection in humans.","volume":"328","author":"Dejnirattisai","year":"2010","journal-title":"Science"},{"key":"R20-20260811","doi-asserted-by":"crossref","first-page":"104490","DOI":"10.1016\/j.meegid.2020.104490","article-title":"Genetic comparison among various coronavirus strains for the identification of potential vaccine targets of SARS-CoV2.","volume":"89","author":"Kaur","year":"2021","journal-title":"Infect Genet Evol"},{"key":"R21-20260811","doi-asserted-by":"crossref","first-page":"1858","DOI":"10.1016\/j.cell.2021.02.010","article-title":"Seasonal human coronavirus antibodies are boosted upon SARS-CoV-2 infection but not associated with protection.","volume":"184","author":"Anderson","year":"2021","journal-title":"Cell"},{"key":"R22-20260811","doi-asserted-by":"crossref","first-page":"eabk0894","DOI":"10.1126\/sciimmunol.abk0894","article-title":"Identification of resident memory CD8+ T cells with functional specificity for SARS-CoV-2 in unexposed oropharyngeal lymphoid tissue.","volume":"6","author":"Niessl","year":"2021","journal-title":"Sci Immunol"},{"key":"R23-20260811","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1126\/science.abe1107","article-title":"Preexisting and de novo humoral immunity to SARS-CoV-2 in humans.","volume":"370","author":"Ng","year":"2020","journal-title":"Science"},{"key":"R24-20260811","doi-asserted-by":"crossref","first-page":"eabd4250","DOI":"10.1126\/science.abd4250","article-title":"Viral epitope profiling of COVID-19 patients reveals cross-reactivity and correlates of severity.","volume":"370","author":"Shrock","year":"2020","journal-title":"Science"},{"key":"R25-20260811","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1038\/s41590-020-00808-x","article-title":"SARS-CoV-2-derived peptides define heterologous and COVID-19-induced T cell recognition.","volume":"22","author":"Nelde","year":"2021","journal-title":"Nat Immunol"},{"key":"R26-20260811","doi-asserted-by":"crossref","first-page":"2037","DOI":"10.1038\/s41467-021-22236-7","article-title":"Systems serology detects functionally distinct coronavirus antibody features in children and elderly.","volume":"12","author":"Selva","year":"2021","journal-title":"Nat Commun"},{"key":"R27-20260811","doi-asserted-by":"crossref","first-page":"2940","DOI":"10.1128\/JCM.00636-10","article-title":"Epidemiology and clinical presentations of the four human coronaviruses 229E, HKU1, NL63, and OC43 detected over 3 years using a novel multiplex real-time PCR method.","volume":"48","author":"Gaunt","year":"2010","journal-title":"J Clin Microbiol"},{"key":"R28-20260811","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.jcv.2018.01.019","article-title":"Human coronavirus circulation in the United States 2014-2017.","volume":"101","author":"Killerby","year":"2018","journal-title":"J Clin Virol"},{"key":"R29-20260811","doi-asserted-by":"crossref","first-page":"394","DOI":"10.7883\/yoken.JJID.2020.525","article-title":"Seasonality of human coronavirus OC43, NL63, HKU1, and 229E infection in Yamagata, Japan, 2010-2019.","volume":"73","author":"Komabayashi","year":"2020","journal-title":"Jpn J Infect Dis"},{"key":"R30-20260811","doi-asserted-by":"crossref","first-page":"515","DOI":"10.3390\/v10100515","article-title":"Human coronavirus infections in Israel: epidemiology, clinical symptoms and summer seasonality of HCoV-HKU1.","volume":"10","author":"Friedman","year":"2018","journal-title":"Viruses"},{"key":"R31-20260811","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1038\/s41467-021-27674-x","article-title":"Cross-reactive memory T cells associate with protection against SARS-CoV-2 infection in COVID-19 contacts.","volume":"13","author":"Kundu","year":"2022","journal-title":"Nat Commun"},{"key":"R32-20260811","doi-asserted-by":"crossref","first-page":"e150449","DOI":"10.1172\/jci.insight.150449","article-title":"Health care worker seromonitoring reveals complex relationships between common coronavirus antibodies and COVID-19 symptom duration.","volume":"6","author":"Gouma","year":"2021","journal-title":"JCI Insight"},{"key":"R33-20260811","doi-asserted-by":"crossref","first-page":"377","DOI":"10.7883\/yoken.JJID.2020.181","article-title":"The first pediatric patients with coronavirus disease 2019 (COVID-19) in Japan: Risk of co-Infection with other respiratory viruses.","volume":"73","author":"Kakuya","year":"2020","journal-title":"Jpn J Infect Dis"},{"key":"R35-20260811","first-page":"1513","article-title":"Regional real-world clinical study of the BNT162b2 vaccine effectiveness against Omicron in children aged 5 to 11 years.","volume":"12","author":"Kakuya","year":"2023","journal-title":"J Jpn Ped Soc"},{"key":"R36-20260811","doi-asserted-by":"crossref","first-page":"e01945","DOI":"10.1128\/JCM.01945-17","article-title":"Multicenter evaluation of BioFire FilmArray Respiratory Panel 2 for detection of viruses and bacteria in nasopharyngeal swab samples.","volume":"56","author":"Leber","year":"2018","journal-title":"J Clin Microbiol"},{"key":"R37-20260811","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1038\/bmt.2012.244","article-title":"Investigation of the freely available easy-to-use software \u201cEZR\u201d for medical statistics.","volume":"48","author":"Kanda","year":"2013","journal-title":"Bone Marrow Transplant"},{"key":"R38-20260811","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1038\/s41591-020-1083-1","article-title":"Seasonal coronavirus protective immunity is short-lasting.","volume":"26","author":"Edridge","year":"2020","journal-title":"Nat Med"},{"key":"R39-20260811","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1017\/S0950268800048019","article-title":"The time course of the immune response to experimental coronavirus infection of man.","volume":"105","author":"Callow","year":"1990","journal-title":"Epidemiol Infect"},{"key":"R40-20260811","doi-asserted-by":"crossref","first-page":"499","DOI":"10.2307\/2531021","article-title":"Sample-size formula for the proportional-hazards regression model.","volume":"39","author":"Schoenfeld","year":"1983","journal-title":"Biometrics"},{"key":"R42-20260811","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.cell.2020.02.052","article-title":"SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor.","volume":"181","author":"Hoffmann","year":"2020","journal-title":"Cell"},{"key":"R43-20260811","doi-asserted-by":"crossref","first-page":"2427","DOI":"10.1001\/jama.2020.8707","article-title":"Nasal gene expression of angiotensin-converting enzyme 2 in children and adults.","volume":"323","author":"Bunyavanich","year":"2020","journal-title":"JAMA"},{"key":"R44-20260811","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.omtm.2020.05.013","article-title":"Airways expression of SARS-CoV-2 receptor, ACE2, and TMPRSS2 is lower in children than adults and increases with smoking and COPD.","volume":"18","author":"Saheb Sharif-Askari","year":"2020","journal-title":"Mol Ther Methods Clin Dev"},{"key":"R45-20260811","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1165\/rcmb.2021-0292OC","article-title":"Age-related differences in the nasal mucosal immune response to SARS-CoV-2.","volume":"66","author":"Koch","year":"2022","journal-title":"Am J Respir Cell Mol Biol"},{"key":"R46-20260811","doi-asserted-by":"crossref","first-page":"e4154","DOI":"10.1093\/cid\/ciaa1911","article-title":"Distinct disease severity between children and older adults with COVID-19: impacts of ACE2 expression, distribution, and lung progenitor cells.","volume":"73","author":"Zhang","year":"2021","journal-title":"Clin Infect Dis"},{"key":"R47-20260811","doi-asserted-by":"crossref","first-page":"5854","DOI":"10.1038\/s41467-020-19587-y","article-title":"Upper airway gene expression reveals suppressed immune responses to SARS-CoV-2 compared with other respiratory viruses.","volume":"11","author":"Mick","year":"2020","journal-title":"Nat Commun"},{"key":"R48-20260811","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1038\/s41590-020-00826-9","article-title":"Distinct antibody responses to SARS-CoV-2 in children and adults across the COVID-19 clinical spectrum.","volume":"2","author":"Weisberg","year":"2021","journal-title":"Nat Immunol"},{"key":"R49-20260811","doi-asserted-by":"crossref","first-page":"eabh1823","DOI":"10.1126\/science.abh1823","article-title":"Cross-reactive CD4+ T cells enhance SARS-CoV-2 immune responses upon infection and vaccination.","volume":"374","author":"Loyal","year":"2021","journal-title":"Science"},{"key":"R50-20260811","doi-asserted-by":"crossref","first-page":"e144499","DOI":"10.1172\/jci.insight.144499","article-title":"Distinct antibody repertoires against endemic human coronaviruses in children and adults.","volume":"6","author":"Khan","year":"2021","journal-title":"JCI Insight"},{"key":"R51-20260811","doi-asserted-by":"crossref","first-page":"1826","DOI":"10.1038\/s41423-021-00700-0","article-title":"Cross-reactive antibody immunity against SARS-CoV-2 in children and adults.","volume":"18","author":"Fraley","year":"2021","journal-title":"Cell Mol Immunol"},{"key":"R52-20260811","doi-asserted-by":"crossref","first-page":"e143380","DOI":"10.1172\/JCI143380","article-title":"Recent endemic coronavirus infection is associated with less-severe COVID-19.","volume":"131","author":"Sagar","year":"2021","journal-title":"J Clin Invest"},{"key":"R53-20260811","doi-asserted-by":"crossref","first-page":"e2213783119","DOI":"10.1073\/pnas.2213783119","article-title":"Recent common human coronavirus infection protects against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection: a Veterans Affairs cohort study.","volume":"119","author":"Fillmore","year":"2022","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R54-20260811","doi-asserted-by":"crossref","first-page":"e2204141119","DOI":"10.1073\/pnas.2204141119","article-title":"Risk of severe COVID-19 infection among adults with prior exposure to children.","volume":"119","author":"Solomon","year":"2022","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R55-20260811","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1016\/j.jinf.2020.10.023","article-title":"Prior presumed coronavirus infection reduces COVID-19 risk: a cohort study.","volume":"81","author":"Aran","year":"2020","journal-title":"J Infect"},{"key":"R56-20260811","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.chom.2021.12.005","article-title":"Pre-existing humoral immunity to human common cold coronaviruses negatively impacts the protective SARS-CoV-2 antibody response.","volume":"30","author":"Lin","year":"2022","journal-title":"Cell Host Microbe"},{"key":"R57-20260811","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1093\/infdis\/jiaa680","article-title":"Analysis of humoral immune responses in patients with severe acute respiratory syndrome coronavirus 2 infection.","volume":"223","author":"Henss","year":"2021","journal-title":"J Infect Dis"},{"key":"R58-20260811","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/S0140-6736(20)30251-8","article-title":"Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding.","volume":"395","author":"Lu","year":"2020","journal-title":"Lancet"},{"key":"R59-20260811","first-page":"1","article-title":"Host factors in coronavirus replication.","volume":"419","author":"de Wilde","year":"2018","journal-title":"Curr Top Microbiol Immunol"},{"key":"R60-20260811","doi-asserted-by":"crossref","first-page":"7988","DOI":"10.1073\/pnas.0409465102","article-title":"Human coronavirus NL63 employs the severe acute respiratory syndrome coronavirus receptor for cellular entry.","volume":"102","author":"Hofmann","year":"2005","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R61-20260811","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/B978-0-12-809633-8.21501-X","article-title":"Human coronavirus-229E, -OC43, -NL63, and -HKU1 (Coronaviridae).","volume":"2","author":"Liu","year":"2021","journal-title":"Encyclo Virol"},{"key":"R62-20260811","doi-asserted-by":"crossref","first-page":"19970","DOI":"10.1073\/pnas.0908837106","article-title":"Crystal structure of NL63 respiratory coronavirus receptor-binding domain complexed with its human receptor.","volume":"106","author":"Wu","year":"2009","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R63-20260811","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1038\/s41586-020-2179-y","article-title":"Structural basis of receptor recognition by SARS-CoV-2.","volume":"581","author":"Shang","year":"2020","journal-title":"Nature"},{"key":"R64-20260811","doi-asserted-by":"crossref","first-page":"103700","DOI":"10.1016\/j.ebiom.2021.103700","article-title":"Relative ratios of human seasonal coronavirus antibodies predict the efficiency of cross-neutralization of SARS-CoV-2 spike binding to ACE2.","volume":"74","author":"Galipeau","year":"2021","journal-title":"EBioMedicine"},{"key":"R65-20260811","doi-asserted-by":"crossref","first-page":"5990","DOI":"10.1038\/s41467-023-41761-1","article-title":"Previous infection with seasonal coronaviruses does not protect male Syrian hamsters from challenge with SARS-CoV-2.","volume":"14","author":"Francis","year":"2023","journal-title":"Nat Commun"},{"key":"R66-20260811","doi-asserted-by":"crossref","first-page":"978440","DOI":"10.3389\/fcimb.2022.978440","article-title":"Pre-existing anti-HCoV-OC43 immunity influences the durability and cross-reactivity of humoral response to SARS-CoV-2 vaccination.","volume":"12","author":"Hu","year":"2022","journal-title":"Front Cell Infect Microbiol"},{"key":"R67-20260811","doi-asserted-by":"crossref","first-page":"e149335","DOI":"10.1172\/JCI149335","article-title":"SARS-CoV-2 mRNA vaccines induce broad CD4+ T cell responses that recognize SARS-CoV-2 variants and HCoV-NL63.","volume":"131","author":"Woldemeskel","year":"2021","journal-title":"J Clin Invest"},{"key":"R68-20260811","doi-asserted-by":"crossref","first-page":"e146927","DOI":"10.1172\/JCI146927","article-title":"Antibody responses to endemic coronaviruses modulate COVID-19 convalescent plasma functionality.","volume":"13","author":"Morgenlander","year":"2021","journal-title":"J Clin Invest"},{"key":"R69-20260811","doi-asserted-by":"crossref","first-page":"21447","DOI":"10.1038\/s41598-020-78506-9","article-title":"Older adults lack SARS CoV-2 cross-reactive T lymphocytes directed to human coronaviruses OC43 and NL63.","volume":"10","author":"Saletti","year":"2020","journal-title":"Sci Rep"},{"key":"R70-20260811","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1038\/s41467-021-20973-3","article-title":"Exploring beyond clinical routine SARS-CoV-2 serology using MultiCoV-Ab to evaluate endemic coronavirus cross-reactivity.","volume":"12","author":"Becker","year":"2021","journal-title":"Nat Commun"},{"key":"R71-20260811","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1038\/s41390-022-02254-x","article-title":"SARS-CoV-2 infection in children and implications for vaccination.","volume":"93","author":"Nathanielsz","year":"2023","journal-title":"Pediatr Res"},{"key":"R72-20260811","doi-asserted-by":"crossref","first-page":"e000040","DOI":"10.1136\/bmjmed-2021-000040","article-title":"COVID-19: virology, variants, and vaccines.","volume":"1","author":"Young","year":"2022","journal-title":"BMJ Med"},{"key":"R73-20260811","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1038\/s41564-022-01143-7","article-title":"SARS-CoV-2 Omicron is an immune escape variant with an altered cell entry pathway.","volume":"7","author":"Willett","year":"2022","journal-title":"Nat Microbiol"}],"container-title":["Pediatric Infectious Disease Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/INF.0000000000005200","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T04:01:00Z","timestamp":1786420860000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/INF.0000000000005200"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,27]]},"references-count":71,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/inf.0000000000005200","relation":{},"ISSN":["0891-3668","1532-0987"],"issn-type":[{"value":"0891-3668","type":"print"},{"value":"1532-0987","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,27]]}}}